TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37036102

Group type: EXPERIMENTAL
Intervention: Nondipping blood pressure pattern
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nondipping blood pressure pattern in patients with carotid artery disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nondipping blood pressure pattern in patients with lower-extremity PVD
Number of subjects: 0
Study: 37036134

Group type: EXPERIMENTAL
Intervention: Paramagnetic rim lesions (PRLs) co-localized with slowly expanding lesions (SELs)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Slowly expanding lesions (SELs)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Chronic MS lesions identified as both PRL and SEL
Number of subjects: 41
Study: 37036155

Group type: EXPERIMENTAL
Intervention: Fluconazole 150-mg capsule (test)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fluconazole 150-mg capsule (reference)
Number of subjects: 36
Study: 37036183

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1227
Study: 37036404

Group type: EXPERIMENTAL
Intervention: 1-dose HAV vaccine
Number of subjects: 153

Group type: COMPARATOR
Intervention: 2-dose HAV vaccine administered 4 weeks apart
Number of subjects: 153

Group type: COMPARATOR
Intervention: 2-dose HAV vaccine (subgroup analysis)
Number of subjects: 153
Study: 37036416

Group type: EXPERIMENTAL
Intervention: Lutein (L) supplementation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Zeaxanthin (Z) supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prenatal supplementation starting at E0 or E11
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Postnatal supplementation starting at P1
Number of subjects: 9
Study: 37036495

Group type: EXPERIMENTAL
Intervention: KarXT
Number of subjects: 68

Group type: COMPARATOR
Intervention: xanomeline alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: KarXT and xanomeline
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: trospium
Number of subjects: 68
Study: 37036560

Group type: EXPERIMENTAL
Intervention: Facilitated subcutaneous immunoglobulin (fSCIG) treatment
Number of subjects: 156
Study: 37036671

Group type: EXPERIMENTAL
Intervention: AZD8186 (120 mg BID, 5 days on/2 days off) plus paclitaxel (80 mg/m2, days 1, 8, and 15) every 4 weeks
Number of subjects: 18
Study: 37036696

Group type: EXPERIMENTAL
Intervention: Decay-Accelerating Factor
Number of subjects: 0
Study: 37036721

Group type: EXPERIMENTAL
Intervention: Coaching intervention (3 one-on-one sessions, 2 with feedback on audio-recorded encounters)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coaching intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no coaching intervention)
Number of subjects: 40
Study: 37036722

Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (20 mg/kg by intravenous infusion every other week for 49 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Avalglucosidase alfa (after switching from alglucosidase alfa)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alglucosidase alfa
Number of subjects: 100
Study: 37036756

Group type: EXPERIMENTAL
Intervention: Riluzole 100 mg PO BID + Sorafenib 400 mg AM/200 mg PM (MTD)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Riluzole + Sorafenib
Number of subjects: 35
Study: 37036783

Group type: EXPERIMENTAL
Intervention: Telehealth intervention for pediatric obesity; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on intervention or control not available.
Number of subjects: 0
Study: 37036793

Group type: EXPERIMENTAL
Intervention: Home-Based Buddhist Walking Meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37036843

Group type: EXPERIMENTAL
Intervention: Health-coach guided diet and exercise intervention (16 weekly sessions in family home)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-coach guided diet and exercise intervention
Number of subjects: 0
Study: 37036890

Group type: EXPERIMENTAL
Intervention: School-based deworming (SBD) reporting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (only school-level reporting of SBD coverage)
Number of subjects: 0
Study: 37037014

Group type: EXPERIMENTAL
Intervention: Reactive stepping intervention
Number of subjects: 0
Study: 37037262

Group type: EXPERIMENTAL
Intervention: Blood test as a second-line option
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group (colonoscopy/FIT only)
Number of subjects: 359
Study: 37037392

Group type: EXPERIMENTAL
Intervention: Hypertension-focused Clinical Decision Support (CDS) plus practice facilitation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Clinical Decision Support (CDS) alone
Number of subjects: 46
Study: 37037458

Group type: EXPERIMENTAL
Intervention: Low-cost standing desk intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 41
Study: 37037584

Group type: EXPERIMENTAL
Intervention: Lymph node yield (LNY) ≥12
Number of subjects: 4575

Group type: COMPARATOR
Intervention: LNY <12
Number of subjects: 4575
Study: 37037585

Group type: EXPERIMENTAL
Intervention: Small tumor-associated macrophages (S-TAMs)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Large tumor-associated macrophages (L-TAMs)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TAM area
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Distribution of L-TAMs
Number of subjects: 84
Study: 37037757

Group type: EXPERIMENTAL
Intervention: XGBoost predictive model
Number of subjects: 369

Group type: COMPARATOR
Intervention: American Fertility Society (AFS) classification
Number of subjects: 369

Group type: COMPARATOR
Intervention: Chinese Society for Gynecological Endoscopy (CSGE) classification
Number of subjects: 369

Group type: COMPARATOR
Intervention: Endometrial thickness
Number of subjects: 369
Study: 37037771

Group type: EXPERIMENTAL
Intervention: Simplified regional citrate anticoagulation (RCA) protocol for CVVH, CVVHDF and SLED-f
Number of subjects: 47
Study: 37037780

Group type: EXPERIMENTAL
Intervention: delgocitinib cream 20 mg/g
Number of subjects: 258

Group type: COMPARATOR
Intervention: cream vehicle
Number of subjects: 258
Study: 37037856

Group type: EXPERIMENTAL
Intervention: Early stoma reversal (within 8-12 days)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Late stoma reversal (> 3 months)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Early stoma reversal
Number of subjects: 146

Group type: COMPARATOR
Intervention: Late stoma reversal
Number of subjects: 146
Study: 37037880

Group type: EXPERIMENTAL
Intervention: Door-to-Door
Number of subjects: 2019

Group type: COMPARATOR
Intervention: Community Health Day
Number of subjects: 2019
Study: 37037948

Group type: EXPERIMENTAL
Intervention: Pen-administered low-dose dasiglucagon
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 37037952

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-059)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-061)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chemotherapy (KEYNOTE-061)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-062)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chemotherapy (KEYNOTE-062)
Number of subjects: 34
Study: 37038006

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin (area under the curve 1.5 mg/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD-L1 blockade
Number of subjects: 0
Study: 37038005

Group type: EXPERIMENTAL
Intervention: Atezolizumab therapy
Number of subjects: 0
Study: 37038105

Group type: EXPERIMENTAL
Intervention: Guided Self-rehabilitation Contract (GSC) involving daily self-rehabilitation program focusing on three facial muscle groups (Frontalis, Orbicularis oculi, Zygomatici) for six months.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Guided Self-rehabilitation Contract (GSC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 82
Study: 37038126

Group type: EXPERIMENTAL
Intervention: CQI intervention for 18 months including reflective sessions, plan-do-study-act cycles, and group mentoring.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Audit-feedback report on access (control group).
Number of subjects: 48
Study: 37038138

Group type: EXPERIMENTAL
Intervention: Active surveillance after neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy
Number of subjects: 0
Study: 37038146

Group type: EXPERIMENTAL
Intervention: Synchronous online pain science education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asynchronous videos pain science education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive e-book pain science education
Number of subjects: 0
Study: 37038159

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg (UPA15)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: adalimumab 40 mg (ADA)
Number of subjects: 0
Study: 37038176

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Childbirth and Parenting (MBCP) intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Active control treatment
Number of subjects: 80
Study: 37038216

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs) embedded in tricalcium phosphate
Number of subjects: 11
Study: 37038235

Group type: EXPERIMENTAL
Intervention: COMPASS for Navigating Pain (COMPASS-NP)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 140
Study: 37038637

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37038736

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37038819

Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in MCI subjects
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in mild AD subjects
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in intact subjects
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in amyloid positive subjects
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in amyloid negative subjects
Number of subjects: 110
Study: 37038875

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: GWW ≥200 mm Hg%
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Longitudinal strain septal contraction patterns 1 and 2
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Positive criteria for echocardiographic assessment of EMD
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Absence of either of the 2 criteria
Number of subjects: 121
Study: 37038897

Group type: EXPERIMENTAL
Intervention: CT-P13 (Inflectra®)
Number of subjects: 2543

Group type: COMPARATOR
Intervention: Reference infliximab (IFX; Remicade®)
Number of subjects: 2543
Study: 37038980

Group type: EXPERIMENTAL
Intervention: PAPP-A blood level measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 0
Study: 37038986

Group type: EXPERIMENTAL
Intervention: Irradiation stent placement with 125 I plus TACE (ISP-TACE)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sorafenib plus TACE (Sora-TACE)
Number of subjects: 105
Study: 37039013

Group type: EXPERIMENTAL
Intervention: Epigenetic age acceleration (EAA) group (n=188)
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Epigenetic age deceleration (EAD) group (n=195)
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: EAA group (n=188)
Number of subjects: 2502
Study: 37039015

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 3048

Group type: COMPARATOR
Intervention: Higher baseline ET-1 concentration
Number of subjects: 3048
Study: 37039068

Group type: EXPERIMENTAL
Intervention: Telehealth integration for alcohol-focused services
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cultural adaptations in telehealth services
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Common workflows for referring clients to treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Research workflows and staff involvement
Number of subjects: 18
Study: 37039338

Group type: EXPERIMENTAL
Intervention: Extemporaneously compounded enteral caffeine base solution
Number of subjects: 0
Study: 37039393

Group type: EXPERIMENTAL
Intervention: Participants on a PIM at baseline
Number of subjects: 19114

Group type: EXPERIMENTAL
Intervention: PIMs exposure
Number of subjects: 19114

Group type: EXPERIMENTAL
Intervention: PPIs, anti-psychotics, and benzodiazepines
Number of subjects: 19114
Study: 37039536

Group type: EXPERIMENTAL
Intervention: Transarticular drilling (TAD)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Retroarticular drilling (RAD)
Number of subjects: 91
Study: 37039792

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Personalized treatment
Number of subjects: 270

Group type: COMPARATOR
Intervention: Lisinopril vs Hydrochlorothiazide
Number of subjects: 270

Group type: COMPARATOR
Intervention: Lisinopril vs Amlodipine
Number of subjects: 270

Group type: COMPARATOR
Intervention: Candesartan vs Hydrochlorothiazide
Number of subjects: 270

Group type: COMPARATOR
Intervention: Candesartan vs Amlodipine
Number of subjects: 270

Group type: COMPARATOR
Intervention: Lisinopril vs Candesartan
Number of subjects: 270

Group type: COMPARATOR
Intervention: Hydrochlorothiazide vs Amlodipine
Number of subjects: 270
Study: 37039791

Group type: EXPERIMENTAL
Intervention: TXA-127 (0.5-mg/kg intravenous infusion once daily for 5 days)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: TRV-027 (12-mg/h continuous intravenous infusion for 5 days)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo (for both trials)
Number of subjects: 343
Study: 37039805

Group type: EXPERIMENTAL
Intervention: Hysteroscopy (n=288)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Vacuum aspiration (n=286) (Control)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 574

Group type: COMPARATOR
Intervention: Vacuum aspiration (Control)
Number of subjects: 574
Study: 37039790

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (n=231)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: ARB (n=217)
Number of subjects: 679

Group type: COMPARATOR
Intervention: Control (n=231)
Number of subjects: 679
Study: 37039948

Group type: EXPERIMENTAL
Intervention: faricimab 6 mg up to every 16 weeks (Q16W) after 4 initial Q4W doses
Number of subjects: 133

Group type: COMPARATOR
Intervention: aflibercept 2 mg Q8W after 3 initial Q4W doses
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: faricimab
Number of subjects: 133

Group type: COMPARATOR
Intervention: aflibercept
Number of subjects: 133
Study: 37039967

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g twice daily, starting from 5 days preoperatively until 10 days postoperatively)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g twice daily)
Number of subjects: 253
Study: 37039975

Group type: EXPERIMENTAL
Intervention: Fluorescence-imaging
Number of subjects: 350

Group type: COMPARATOR
Intervention: Clinical signs and symptoms of infection (CSS)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Sensitivity to detect TBL >10
Number of subjects: 350
Study: 37040046

Group type: EXPERIMENTAL
Intervention: MK-8353/selumetinib 100/50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MK-8353/selumetinib 150/75 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MK-8353/selumetinib (all doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MK-8353/selumetinib 50/25 mg and 100/50 mg
Number of subjects: 30
Study: 37040086

Group type: EXPERIMENTAL
Intervention: Bivalent HPV 16/18 vaccine
Number of subjects: 3727
Study: 37040116

Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg biweekly
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg monthly
Number of subjects: 854

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 854
Study: 37040167

Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) intervention group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) control group
Number of subjects: 120
Study: 37040172

Group type: EXPERIMENTAL
Intervention: Feature selection methods and classification approaches (support vector machine, logistic regression, decision trees, random forest, extra-trees)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Transcriptomic data inclusion in classification approaches
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DESeq2 as a feature selection method and extra-trees classifier
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Identification of 5 genes (CDIPT, MRC2, PATL2, RFXANK, SUMO3)
Number of subjects: 56
Study: 37040304

Group type: EXPERIMENTAL
Intervention: Serious Illness Conversation Training for Interprofessional Primary Care Teams
Number of subjects: 0
Study: 37040386

Group type: EXPERIMENTAL
Intervention: Individuals with cancer
Number of subjects: 213

Group type: COMPARATOR
Intervention: Individuals without cancer
Number of subjects: 213
Study: 37040388

Group type: EXPERIMENTAL
Intervention: Protein-altering variants in cytotoxicity genes in IRIS patients (n = 56)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Protein-altering variants in cytotoxicity genes in non-IRIS patients (n = 26)
Number of subjects: 82
Study: 37040544

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 37040553

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CADx)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Endoscopist predictions
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: CADx
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: CADx and endoscopist predictions
Number of subjects: 320
Study: 37040726

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 291
Study: 37040839

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 476

Group type: COMPARATOR
Intervention: Electronic medical record portal messaging
Number of subjects: 476
Study: 37040850

Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 0 (11.6%)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 1 (19.5%)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 2 to 3 (29.4%)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 4 to 5 (31.5%)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Severe postoperative disability (mRS 4 to 5)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Moderate postoperative disability (mRS 2 to 3)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 0
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 1
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 2 to 3
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 4 to 5
Number of subjects: 1178
Study: 37040861

Group type: EXPERIMENTAL
Intervention: Dynamic Coronary Roadmap (DCR) guidance during PCI
Number of subjects: 394

Group type: COMPARATOR
Intervention: Standard PCI without DCR guidance
Number of subjects: 394
Study: 37041046

Group type: EXPERIMENTAL
Intervention: Ketamine mouthwash (4 times daily for 2 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ketamine mouthwash
Number of subjects: 23
Study: 37041057

Group type: EXPERIMENTAL
Intervention: Oral immunonutritional supplement (INS) for 6 months
Number of subjects: 696

Group type: COMPARATOR
Intervention: Normal diet for 6 months
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Oral immunonutritional supplement (INS)
Number of subjects: 696
Study: 37041063

Group type: EXPERIMENTAL
Intervention: CRP POCT intervention
Number of subjects: 0
Study: 37041081

Group type: EXPERIMENTAL
Intervention: Acute encephalopathy in patients with severe COVID-19
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Age older than 70 years
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Presumed fatal comorbidity
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Glasgow coma scale score <9 before/at ICU admission
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Vasopressor/inotrope support during ICU stay
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy during ICU stay
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: CNS ischemic or hemorrhagic complications as acute encephalopathy etiology
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome
Number of subjects: 374
Study: 37041205

Group type: EXPERIMENTAL
Intervention: D-Cycloserine (100 mg) with repeated spaced iTBS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo with repeated spaced iTBS
Number of subjects: 20
Study: 37041472

Group type: EXPERIMENTAL
Intervention: BPI-9016M 300 mg QD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BPI-9016M 450 mg QD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BPI-9016M 600 mg QD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BPI-9016M 400 mg BID (Part B)
Number of subjects: 38